Table 1.
Baseline Characteristics of the Study Population (N = 39)
| Characteristic | Value |
|---|---|
| Age, y, mean (SD) | 64.6 (10.7) |
| BMI, kg/m2, mean (SD) | 31.6 (7.6) |
| EF, %, mean (SD) | 53 (13) |
| Male sex, n (%) | 31 (80) |
| Hypertension, n (%) | 32 (82) |
| Hyperlipidemia, n (%) | 35 (90) |
| Current smoker, n (%) | 6 (15) |
| DM, n (%) | 17 (44) |
| CKD, n (%) | 5 (13) |
| History of prior MI, n (%) | 17 (44) |
| History of CHF, n (%) | 7 (18) |
| Reason for catheterization, n (%) | |
| Stable angina | 3 (8) |
| UA or NSTEMI | 28 (72) |
| STEMI | 3 (8) |
| Coronary anatomy, n (%) | |
| Left‐main disease | 13 (33) |
| ≥3‐vessel disease | 25 (64) |
| 2‐vessel disease | 10 (26) |
| 1‐vessel disease | 4 (10) |
| Medications in prior 24 hours, n (%) | |
| Unfractionated heparin | 21 (54) |
| Enoxaparin | 5 (13) |
| Glycoprotein IIb/IIIa inhibitor | 6 (15) |
| β‐Blocker | 36 (93) |
| ACEI/ARB | 29 (76) |
| Statin | 20 (51) |
| Aspirin | 37 (95) |
| <324 mg | 6 (15) |
| ≥324 mg | 31 (80) |
| Laboratory parameters, mean (SD) | |
| BUN, mg/dL | 19 (7) |
| Cr, mg/dL | 1.2 (1.1) |
| PT, sec | 14.0 (1.5) |
| aPTT, sec | 44.6 (20.8) |
| Platelet count, thousands, mm3 | 238 (78) |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; aPTT, activated partial thromboplastin time; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CHF, congestive heart failure; CKD, chronic kidney disease; Cr, creatinine; DM, diabetes mellitus; EF, ejection fraction; MI, myocardial infarction; NSTEMI, non–ST‐segment elevation myocardial infarction; PT, prothrombin time; SD, standard deviation; STEMI, ST‐segment elevation myocardial infarction; UA, unstable angina.